NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
NRx Pharmaceuticals (NASDAQ:NRXP) has submitted the first section of its New Drug Application (NDA) for NRX-100 (ketamine) to the FDA for treating suicidal depression. The company aims to be the first to receive FDA approval for this indication, addressing a market of over 13 million Americans who consider suicide annually.
The initial submission includes an 1800-page manufacturing section (Module 3), with final efficacy data and remaining sections expected in Q1 2025. NRX-100's formulation differs from anesthetic ketamine by excluding toxic preservatives and featuring diversion-resistant packaging. The drug, which received Fast Track Designation in 2017, represents a potential $3-5 billion market based on CDC data indicating 3.8 million Americans plan suicide annually.
NRx Pharmaceuticals (NASDAQ:NRXP) ha presentato la prima sezione della sua Domanda di Nuovo Farmaco (NDA) per NRX-100 (ketamina) alla FDA per il trattamento della depressione suicidaria. L'azienda punta a essere la prima a ricevere l'approvazione della FDA per questa indicazione, affrontando un mercato di oltre 13 milioni di americani che considerano il suicidio ogni anno.
La presentazione iniziale include una sezione di produzione di 1800 pagine (Modulo 3), con dati finali di efficacia e le sezioni rimanenti previste per il primo trimestre del 2025. La formulazione di NRX-100 si differenzia dalla ketamina anestetica escludendo conservanti tossici e presentando un imballaggio resistente alla diversione. Il farmaco, che ha ricevuto la Designazione Fast Track nel 2017, rappresenta un mercato potenziale di 3-5 miliardi di dollari basato su dati del CDC che indicano che 3,8 milioni di americani pianificano il suicidio ogni anno.
NRx Pharmaceuticals (NASDAQ:NRXP) ha presentado la primera sección de su Solicitud de Nuevo Medicamento (NDA) para NRX-100 (ketamina) a la FDA para el tratamiento de la depresión suicida. La compañía busca ser la primera en recibir la aprobación de la FDA para esta indicación, abordando un mercado de más de 13 millones de estadounidenses que consideran el suicidio anualmente.
La presentación inicial incluye una sección de fabricación de 1800 páginas (Módulo 3), con datos finales de eficacia y secciones restantes que se esperan para el primer trimestre de 2025. La formulación de NRX-100 se diferencia de la ketamina anestésica al excluir conservantes tóxicos y presentar un embalaje resistente a la desviación. El fármaco, que recibió la designación Fast Track en 2017, representa un mercado potencial de 3-5 mil millones de dólares basándose en datos de los CDC que indican que 3.8 millones de estadounidenses planean suicidarse anualmente.
NRx 제약(NASDAQ:NRXP)는 자살 우울증 치료를 위한 NRX-100(케타민)의 신약 신청(NDA) 첫 번째 섹션을 FDA에 제출했습니다. 이 회사는 매년 자살을 고려하는 1,300만 명 이상의 미국인을 대상으로 하는 이 적응증에 대해 FDA 승인을 최초로 받기 위해 노력하고 있습니다.
초기 제출물에는 1,800페이지 분량의 제조 섹션(모듈 3)이 포함되어 있으며, 최종 효능 데이터와 남은 섹션은 2025년 1분기로 예정되어 있습니다. NRX-100의 제형은 독성 방부제를 제외하고 전용 방지 포장을 특징으로 하여 마취용 케타민과 다릅니다. 2017년에 신속 승인 지정을 받은 이 약물은 매년 380만 명의 미국인이 자살을 계획하고 있다는 CDC 데이터를 기반으로 미화 30억~50억 달러의 잠재적 시장을 나타냅니다.
NRx Pharmaceuticals (NASDAQ:NRXP) a soumis la première section de sa Demande de Nouveau Médicament (NDA) à la FDA pour NRX-100 (kéthamine) dans le traitement de la dépression suicidaire. L'entreprise vise à être la première à obtenir l'approbation de la FDA pour cette indication, ciblant un marché de plus de 13 millions d'Américains qui envisagent le suicide chaque année.
La soumission initiale comprend une section de fabrication de 1800 pages (Module 3), avec des données d'efficacité finales et des sections restantes attendues au premier trimestre 2025. La formulation de NRX-100 se distingue de la kétamine anesthésique en excluant des conservateurs toxiques et en présentant un emballage résistant à la détournement. Le médicament, qui a reçu la désignation Fast Track en 2017, représente un marché potentiel de 3 à 5 milliards de dollars sur la base des données des CDC indiquant que 3,8 millions d'Américains prévoient de se suicider chaque année.
NRx Pharmaceuticals (NASDAQ:NRXP) hat den ersten Abschnitt seines Antrags auf Zulassung eines neuen Arzneimittels (NDA) für NRX-100 (Ketamin) bei der FDA zur Behandlung von suizidalen Depressionen eingereicht. Das Unternehmen strebt an, als erstes die FDA-Zulassung für diese Indikation zu erhalten und richtet sich an einen Markt von über 13 Millionen Amerikanern, die jährlich an Suizid denken.
Die erste Einreichung umfasst einen 1800-seitigen Herstellungsabschnitt (Modul 3), wobei die endgültigen Wirksamkeitsdaten und die verbleibenden Abschnitte für das erste Quartal 2025 erwartet werden. Die Formulierung von NRX-100 unterscheidet sich von anästhetischem Ketamin, da sie toxische Konservierungsmittel ausschließt und eine ablenkungsresistente Verpackung aufweist. Das Medikament, das 2017 den Fast Track-Status erhielt, stellt einen potenziellen Markt von 3-5 Milliarden Dollar dar, basierend auf CDC-Daten, die angeben, dass jährlich 3,8 Millionen Amerikaner Suizid planen.
- Fast Track Designation received for NRX-100
- Potential $3-5 billion market opportunity
- Product already in use by Department of Defense and Veterans Affairs
- First section of NDA submitted to FDA
- Complete NDA submission delayed until Q1 2025
- Product has known abuse potential
- Currently lacks insurance reimbursement coverage
- Faces competition from existing off-label ketamine use
Insights
The FDA submission for NRX-100 represents a potential breakthrough in treating suicidal depression. The unique formulation, free of toxic preservatives and featuring diversion-resistant packaging, addresses key safety concerns in ketamine administration. The Fast Track Designation since 2017 and the FDA's request for early manufacturing data review signals regulatory prioritization.
The market opportunity is substantial with
The phased NDA submission strategy, starting with the 1,800-page manufacturing section, suggests a well-organized approach to regulatory compliance. The planned Q1 2025 complete submission timeline appears realistic given the extensive clinical data already available from NIH and European government-funded trials.
This regulatory milestone could significantly impact NRXP's market position. With a current market cap of just
Insurance reimbursement post-FDA approval would be transformative for revenue potential. The existing off-label ketamine market demonstrates proven demand, but lack of insurance coverage has widespread adoption. VA and DOD coverage provides a blueprint for broader insurance acceptance, potentially driving rapid market penetration upon approval.
The regulatory strategy aligns with current healthcare crisis management priorities. With 3.8 million Americans planning suicide annually, FDA approval would establish a standardized treatment protocol, potentially improving healthcare system response to acute suicidal ideation. The diversion-resistant packaging addresses key controlled substance regulatory requirements, potentially facilitating broader institutional adoption.
The expansion from the original bipolar depression indication to include Major Depressive Disorder demonstrates strategic positioning to address broader mental health needs. This could influence treatment guidelines and insurance coverage policies, potentially establishing NRX-100 as a first-line intervention for suicidal ideation across multiple depression subtypes.
- Aiming to be the first FDA-approved medication to treat suicidal depression
- Designed to help address the needs of the more than 13 million Americans who seriously consider suicide each year (CDC)
- Completion of NDA filing expected in the first quarter of 2025
- Company to participate in 1x1 meetings in
San Francisco during the Annual J.P. Morgan Healthcare Conference on January 13-16, 2025, inSan Francisco , CA. To schedule meetings, please contact jpm@astrpartners.com
While assembly of the clinical data sections is being completed, FDA has asked the Company to submit the 1800-page manufacturing section (Module 3) of the NDA to enable immediate review prior to submission of final efficacy data and other sections of the NDA expected in the first quarter of 2025.
The NRx presentation of ketamine differs from the form of ketamine used in anesthesia in that it contains no potentially toxic preservatives and utilizes diversion-resistant packaging to enhance the traceability of a medicine known to have abuse potential.
Suicidal depression is considered a national crisis. According to the CDC over 13 million Americans seriously consider suicide each year and 3.8 million make a plan to do so.
"New treatment options are urgently needed for people at risk with acute suicidal depression," said Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist. "Ketamine is already widely-used for the treatment of suicidal depression on an off-label basis and is funded by the Department of Defense and the Department of Veterans Affairs. However, without FDA approval, its use is largely unreimbursed by health insurers, with the exception of VA and DOD."
NRx thanks its shareholders, its clinical team, and the many patients and caregivers who have participated in the clinical trials.
NRX-100 (IV ketamine) for Suicidal Depression
Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has begun submission of a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of precision psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-files-initial-section-of-us-new-drug-application-to-the-fda-for-nrx-100-iv-ketamine-for-the-treatment-of-suicidal-depression-302340035.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
When will NRXP complete the full NDA submission for NRX-100?
What is the market size potential for NRXP's NRX-100 ketamine treatment?
How does NRXP's NRX-100 differ from traditional ketamine?
When did NRXP receive Fast Track Designation for NRX-100?
Which government agencies currently support NRXP's ketamine treatment?
